Eva Jack (pictured), managing director at AstraZeneca’s corporate venturing unit MedImmune Ventures, has left to become chief business officer at Novartis-backed Pulmatrix.
Jack’s move comes after the transition of the US-based team’s other managing directors, Maggie LeFlore and Frank Top, to become venture partners.
In April, Ron Laufer, a co-founder of Lilly Ventures, was hired as senior managing director. Laufer has recruited Samuel Wu, ex-principal at SV Life Sciences for eight years, and Isai Peimer as a principal.